Trial · NCT01958580
Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
NCT01958580, Not applicable, Terminated, Albert Einstein College of Medicine; results first posted 2023-08-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery. Trials, record NCT01958580. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01958580
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery
- NCT number
- NCT01958580
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 3 participants, actual
- Lead sponsor
- Albert Einstein College of Medicine
- Conditions
Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Uterine Corpus Leiomyosarcoma
- Interventions
- Gemcitabine Hydrochloride, Docetaxel, Internal Radiation Therapy, Intensity-Modulated Radiation Therapy, External Beam Radiation Therapy, Laboratory Biomarker Analysis
- First posted
- 2013-10-09
- Last updated
- 2023-08-16
- Results first posted
- 2023-08-16
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recurrence-free Survival | Date of entry to date of reappearance of disease, assessed at 2 years. The study was terminated prior to analyses | Two-year recurrence-free survival probability will be estimated, with 95% confidence limits based on exact methods for the binomial distribution. In the event of censoring before two years, a Kaplan-Meier estimate of the survival probability will be used and a Kaplan-Meier survival curve will be estimated and presented as well. The study was terminated prior to analyses |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Recurrence-free Survival | Date of entry to date of reappearance of disease, assessed at 2 years. The study was terminated prior to analyses | Data pertaining to Recurrence-free Survival was not collected/aggregated and therefore not analyzed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT/EBRT) | 3 | |
| Overall Study | COMPLETED | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT/EBRT) | 3 | |
| Overall Study | NOT COMPLETED | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT/EBRT) | 0 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 6 |
| other | Skin Hyperpigmentation | Skin and subcutaneous tissue disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
| other | Edema Limbs | General disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 2 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 2 |
| other | Nephrotoxicity | Renal and urinary disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
| other | Shoulder Pain | Musculoskeletal and connective tissue disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
| other | Peripheral Neuropathy | Nervous system disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
| other | Fatigue | General disorders | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 | 1 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 0 | 3 |
| Total, other adverse events | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 |
| Total, serious adverse events | Treatment (Gemcitabine, Docetaxel, Brachytherapy/IMRT, EBRT) | 1 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA013330 | Cancer Center Support Grant | STEIDL, ULRICH | ALBERT EINSTEIN COLLEGE OF MEDICINE | NATIONAL CANCER INSTITUTE | 1985 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01958580
GET https://conductscience.org/api/trials/v1/NCT01958580/registered